These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 25613306)

  • 21. IV tissue plasminogen activator for stroke in the community: what we know and don't know 10 years after FDA approval.
    Furlan AJ
    Stroke; 2006 Feb; 37(2):281. PubMed ID: 16397163
    [No Abstract]   [Full Text] [Related]  

  • 22. Barriers to delivery of thrombolysis for acute stroke.
    Barber M; Langhorne P; Stott DJ
    Age Ageing; 2004 Mar; 33(2):94-5. PubMed ID: 14960419
    [No Abstract]   [Full Text] [Related]  

  • 23. Yes, intravenous thrombolysis should be administered in pregnancy when other clinical and imaging factors are favorable.
    Demchuk AM
    Stroke; 2013 Mar; 44(3):864-5. PubMed ID: 23391770
    [No Abstract]   [Full Text] [Related]  

  • 24. Transition of European Cooperative Acute Stroke Study III results to clinical practice: ninety-day outcomes in a US cohort.
    Cronin CA; Langenberg P; Dutta TM; Kittner SJ
    Stroke; 2013 Dec; 44(12):3544-6. PubMed ID: 24092551
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictive value of the Cincinnati Prehospital Stroke Scale for identifying thrombolytic candidates in acute ischemic stroke.
    You JS; Chung SP; Chung HS; Lee HS; Park JW; Kim HJ; Lee SH; Park I; Lee HS
    Am J Emerg Med; 2013 Dec; 31(12):1699-702. PubMed ID: 24055479
    [TBL] [Abstract][Full Text] [Related]  

  • 26. IV and IA thrombolytic stroke strategies are complementary.
    Donnan GA; Davis SM
    Stroke; 2009 Jul; 40(7):2615. PubMed ID: 19443794
    [No Abstract]   [Full Text] [Related]  

  • 27. Predictors of good clinical outcome in acute stroke patients treated with intravenous thrombolysis.
    Saňák D; Herzig R; Zapletalová J; Horák D; Král M; Skoloudík D; Bártková A; Veverka T; Heřman M; Kaňovský P
    Acta Neurol Scand; 2011 May; 123(5):339-44. PubMed ID: 20597864
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stroke thrombolysis in Mombasa--an outreach service.
    Cohen D
    Pract Neurol; 2011 Dec; 11(6):372-4. PubMed ID: 22100952
    [No Abstract]   [Full Text] [Related]  

  • 29. Arterial occlusive lesions recanalize more frequently in women than in men after intravenous tissue plasminogen activator administration for acute stroke.
    Savitz SI; Schlaug G; Caplan L; Selim M
    Stroke; 2005 Jul; 36(7):1447-51. PubMed ID: 15947268
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Update on intravenous recombinant tissue plasminogen activator for acute ischemic stroke.
    Fugate JE; Rabinstein AA
    Mayo Clin Proc; 2014 Jul; 89(7):960-72. PubMed ID: 24775222
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intravenous thrombolysis for stroke.
    Derex L
    BMJ; 2010 Nov; 341():c5891. PubMed ID: 21098612
    [No Abstract]   [Full Text] [Related]  

  • 32. Decision for intravenous thrombolysis in a young patient with acute vertical gaze palsy.
    Papadopoulou A; Ahlhelm FJ; Lyrer P; Kuhle J
    Acta Neurol Belg; 2015 Sep; 115(3):445-7. PubMed ID: 25182748
    [No Abstract]   [Full Text] [Related]  

  • 33. Intravenous thrombolysis with recombinant tissue plasminogen activator in vascular warning syndromes.
    González Hernández A; Fabre Pi O; Cabrera Naranjo F; López Veloso AC
    Neurologia; 2014; 29(6):334-8. PubMed ID: 24139385
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Utilization of intravenous tissue plasminogen activator for acute ischemic stroke.
    Katzan IL; Hammer MD; Hixson ED; Furlan AJ; Abou-Chebl A; Nadzam DM;
    Arch Neurol; 2004 Mar; 61(3):346-50. PubMed ID: 15023810
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Age and Stroke Severity: Hazards for Intravenous Thrombolysis?
    Long C; Li M
    Med Princ Pract; 2016; 25(1):99-100. PubMed ID: 26457894
    [No Abstract]   [Full Text] [Related]  

  • 36. Is intraarterial tPA within 3 hours the treatment of choice for selected stroke patients?: No.
    Lindley RI
    Stroke; 2009 Jul; 40(7):2613-4. PubMed ID: 19443793
    [No Abstract]   [Full Text] [Related]  

  • 37. Standard-dose intravenous tissue-type plasminogen activator for stroke is better than low doses.
    Liao X; Wang Y; Pan Y; Wang C; Zhao X; Wang DZ; Wang C; Liu L; Wang Y;
    Stroke; 2014 Aug; 45(8):2354-8. PubMed ID: 25013020
    [TBL] [Abstract][Full Text] [Related]  

  • 38. De-novo thrombolysis for recurrent stroke in a patient with prior history of thrombolysis.
    Arsava EM; Topcuoglu MA
    Blood Coagul Fibrinolysis; 2010 Sep; 21(6):605-7. PubMed ID: 20644467
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Estimated weight is not a reliable measure for dosing tissue plasminogen activator for thrombolysis in acute ischaemic stroke.
    Gill D; Halsey L; Kalkat H; Patel S; Kar A
    Int J Stroke; 2016 Feb; 11(2):NP25-6. PubMed ID: 26783320
    [No Abstract]   [Full Text] [Related]  

  • 40. Magnetic resonance imaging-guided thrombolysis in minor stroke.
    Desilles JP; Cho TH; Hermier M; Mechtouff-Cimarelli L; Derex L; Nighoghossian N
    Int J Stroke; 2011 Apr; 6(2):178. PubMed ID: 21371285
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.